As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

By May of 2025, Novo's now-former chief executive, Lars Fruergaard Jørgensen, announced that he would be stepping down, ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Lars Fruergaard Jørgensen, der stoppede som direktør i Novo Nordisk for få måneder siden, har allerede varslet, at der ville ...

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

Mike Doustdar, der er ny direktør i Novo Nordisk fortalte på sin første dag, at man ikke kunne undgå fyringer. Og det skulle ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

De sidste par år har Novo Nordisk ansat flere tusinde medarbejdere årligt i Danmark og resten af verden. Men det slutter nu.

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for ...